APOTHEEK BLINDEMAN CISKA
ActiveSummary
APOTHEEK BLINDEMAN CISKA has been active since 2015 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €156,561 and a net result of €44,568. Equity has been growing by about 26% per year since 2018. Its solvency ranks better than 29% of 12,775 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.8% (low).
Overview
Official details
Source: KBO- Status
- Active since 14-04-2015 Normal situation
- Activity
- Retail sale of pharmaceutical products NACE 47730
- Joint committee
- 313 Paritair Comité voor de apotheken en tarificatiediensten · annual accounts 2022
- Establishment unit
- 2.241.638.128 9000 Gent, since 14-04-2015
- Financial year end
- 31 December
- Peppol
- Reachable since 09-12-2025
Financial position
- Bankruptcy probabilitywithin 12 months
- 0.8%
- Gross margin
- €254,287
- ▲ 12.6%
- Turnover
- ≈ €930,000
- estimated
- Profit
- €44,568
- ▲ 403%
- Equity
- €156,561
- ▲ 39.8%
- Total assets
- €854,785
- ▼ 3.5%
- Employees on 31-12-2025
- 2
- ▼ 33.3%
- 2025 accounts filed 31 days after the deadline
Score breakdownraises riskLast filed accounts filed 31 days late; 2 of the last 3 accounts lateEquity €156,561 (18.3% of total assets)lowers riskSize: 1.7 FTE, total assets €854,785Founded in 2015Show the evidence
Checked score
About 8 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 34% of them on solvency, 25% on liquidity, 62% on profitability and 83% on growth.
The bankruptcy probability was computed on 02-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 7 accounts on average 30 days after the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Searched, nothing found (2)
Key points
- Positive: 7 profitable years in a rowprofit 2025: €44,568 7 years View
Recent changes
- · Gazette deed Incorporation
Comparable companies
These companies have the same main activity as APOTHEEK BLINDEMAN CISKA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €692,000 and €976,000, founded between 2013 and 2016.
| Company | Total assets | Gross margin |
|---|---|---|
| APOTHEEK BLINDEMAN CISKA Gent | €854,785 | €254,287 |
| PHARMACIE LATINIS Schaarbeek | €839,336 | €260,512 |
| BRUYAUX PHARMA Mons | €856,915 | €244,813 |
| PHARMACIE CHARLEZ-CORSINI La Louvière | €940,131 | €239,545 |
| APOTHEEK MUIZEN Mechelen | €901,594 | €266,820 |
| Apotheek Bambrugge Erpe-Mere | €692,238 | €236,256 |
| PHARMAPLUS INVEST Vorst | €976,007 | €274,101 |
Key facts about APOTHEEK BLINDEMAN CISKA
- What is the company number of APOTHEEK BLINDEMAN CISKA?
- The company number of APOTHEEK BLINDEMAN CISKA is 0628.749.446. The VAT number is the same number with BE in front: BE 0628.749.446.
- Where is APOTHEEK BLINDEMAN CISKA based?
- The registered office is at Papegaaistraat 80, 9000 Gent.Company details
- What does APOTHEEK BLINDEMAN CISKA do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of APOTHEEK BLINDEMAN CISKA?
- The legal form of APOTHEEK BLINDEMAN CISKA is Private limited company (BV).
- When was APOTHEEK BLINDEMAN CISKA founded?
- APOTHEEK BLINDEMAN CISKA was founded on 14-04-2015.
- Is APOTHEEK BLINDEMAN CISKA still active?
- Yes, APOTHEEK BLINDEMAN CISKA is an active enterprise in the KBO register.
- How many employees does APOTHEEK BLINDEMAN CISKA have?
- APOTHEEK BLINDEMAN CISKA had an average of 1.7 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does APOTHEEK BLINDEMAN CISKA fall under?
- In its 2022 annual accounts, APOTHEEK BLINDEMAN CISKA states joint committee 313 (Paritair Comité voor de apotheken en tarificatiediensten).
- What is the turnover of APOTHEEK BLINDEMAN CISKA?
- The turnover in financial year 2025 is ≈ €930,000. This figure is estimated from the gross margin of €254,287 and 47 comparable companies (NACE 477). It probably lies between €720,000 and €1.5m.
- Is APOTHEEK BLINDEMAN CISKA profitable?
- In financial year 2025, APOTHEEK BLINDEMAN CISKA made a profit of €44,568.
- Where can I find the annual accounts of APOTHEEK BLINDEMAN CISKA?
- APOTHEEK BLINDEMAN CISKA filed 10 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of APOTHEEK BLINDEMAN CISKA due?
- APOTHEEK BLINDEMAN CISKA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
See how customers, suppliers and banks see your own company and what to improve first.